Ke hoʻomau nei ka piʻi ʻana o nā hihia olakino noʻonoʻo a ke lawe nei i kahi pōʻino koʻikoʻi i ka ʻōnaehana olakino. ʻO ka mea pōmaikaʻi, ke kūkulu ʻia nei nā psychedelics e like me DMT, psilocybin, MDMA, a me LSD e mālama i nā maʻi psychiatric like ʻole e like me ke kaumaha, ka hopohopo, a me ka PTSD. ʻO kahi noiʻi a nā mea noiʻi ma Johns Hopkins Medicine e hōʻike ana i ka mālama ʻana i ka psychedelic me psilocybin i hoʻomaha i nā hōʻailona o ka maʻi depressive nui no ka liʻiliʻi o hoʻokahi makahiki no kekahi mau maʻi. Ua hōʻike ʻia kahi noiʻi ʻē aʻe mai nā kānaka ʻepekema ma McGill University e hōʻemi ana nā haʻahaʻa haʻahaʻa maʻamau o LSD i nā hōʻailona hopohopo ma o nā hana neurobiological e like me nā antidepressants maʻamau. Ua alakaʻi nā hopena maikaʻi i ka hoihoi o nā mea hoʻopukapuka, me ke kālā no nā hui lāʻau psychedelic ma mua o $ 700 miliona ma 2021.
Ua hoʻokumu ʻo Cybin Inc. i kahi kūlana alakaʻi i ka psychedelic therapeutic space e pili ana i kāna ʻano ʻepekema proprietary a me ka kaiaola hoʻomohala lāʻau.
Ma Malaki 29, ua hoʻolaha ʻo Cybin ua hoʻopau maikaʻi ʻo ia i nā haʻawina preclinical in vivo e loiloi ana i kāna deuterated psilocybin analog CYB003 no ka mālama ʻana i ka maʻi depressive nui (MDD). Hōʻike ka ʻikepili mai nā haʻawina preclinical in vivo ua ʻae maikaʻi ʻia ʻo CYB003 ma hope o nā kau he nui i nā ʻano he nui. Hoʻolālā ʻo Cybin e waiho i kahi hoʻopiʻi Investigational New Drug (IND) me ka US Food and Drug Administration (FDA) i ka lua o ka hapaha o 2022 a e hoʻomaka i ka hoʻokolohua lapaʻau Phase 1/2a i ka waena o 2022.
"ʻO ka hoʻopau ʻana i kēia mau haʻawina preclinical in vivo no CYB003 he mea koʻikoʻi loa ia i ka holomua ʻana i kēia papahana i ka hoʻomohala mua-i-kanaka a lawe mai iā mākou i kahi ʻanuʻu kokoke i ka holomua ʻana o CYB003 ma ke ʻano he moho lapaʻau maikaʻi loa no ka maʻi noʻonoʻo a me ka hoʻohui. , "wahi a Cybin CEO Doug Drysdale. "Hoʻolālā mākou e kālele i ka hoʻokolokolo Phase 1/2a ma United States. Ke manaʻoʻiʻo nei mākou e ʻae kēia iā mākou e hoʻonui i ka noiʻi ma o ka hoʻomohala mua ʻana o ka lāʻau lapaʻau a i loko o kahi hoʻāʻo ākea Phase 2b, ʻoiai e hōʻiliʻili ana i ka nui o ka ʻikepili e kākoʻo i nā haʻawina hope.
Ua hoʻolaha hou aku ʻo Cybin ua hui pū ʻo ia me ka Chopra Foundation e hoʻonui i ka hoʻonaʻauao a me ka ʻike i ka hoʻohana ʻana o nā psychedelics e kākoʻo i ka olakino a me ke olakino noʻonoʻo. Hōʻike nā noiʻi hou e hiki i ka psychedelic-assisted therapy ke hoʻomaikaʻi i ka maikaʻi o ke ola no ka poʻe me nā maʻi noʻonoʻo.
Ma waho aʻe o kāna mau papahana hoʻomohala lāʻau lapaʻau preclinical, hoʻomaʻamaʻa a me ka noiʻi ʻana, kaʻana like ʻo Cybin i ka manaʻo o ka Chopra Foundation e hōʻoia i ka loaʻa ʻana o nā kumuwaiwai olakino no nā mea āpau, me ka poʻe i loko o nā kaiāulu underserved.
"Hoʻohanohano ʻia mākou e hui pū me ka Chopra Foundation, a ʻo ia hoʻi, e lilo i ʻāpana o ka NeverAlone Initiative. Nui ka hoʻomaopopo ʻana e pili ana i nā psychedelics, ʻoiai ua aʻo ʻia lākou ma ke kula no nā makahiki he mau makahiki, akā nui nā hana noiʻi e hana ʻia, "wahi a Cybin CEO Doug Drysdale. "Ma Cybin, ke hoʻohana nei mākou i nā ʻenehana lāʻau lapaʻau a me nā ʻenehana hāʻawi lāʻau lapaʻau e kūkulu ma luna o ka ʻikepili lapaʻau i loaʻa a hoʻomaikaʻi i ka ʻike maʻi ma o ka lanakila ʻana i nā palena o nā lāʻau lapaʻau i kēia manawa no ka maʻi noʻonoʻo."
I ka mahina i hala aku nei, ua hoʻopuka ʻo Cybin i nā hualoaʻa Q3 me ke kālā a me ke kālā like me ka huina o C $ 63.6 miliona mai ka lā 31 o Dekemaba, 2021. ʻO nā lilo hana kālā he C $ 12 miliona no ka hapaha i pau i ka lā 31 Dekemaba 2021, ʻo ia ka C $ 2.5 miliona i hoʻokahi manawa, ʻaʻole. -koki mau. ʻO nā lilo kālā ʻole he $5.2 miliona no ka poho ʻupena o C$17.2 miliona.
Ua hōʻike pū ʻo Cybin i kekahi mau mea koʻikoʻi ʻē aʻe, me ka hoʻopau ʻana ma luna o 140 mau noiʻi pre-clinical e kākoʻo ana i ka holomua o CYB003, CYB004, a me nā molekole psychedelic proprietary e pili ana i nā faila hoʻoponopono, e hōʻailona ana i 50+ mau haʻawina preclinical hou i hoʻopau ʻia ma Ianuali 2022 wale nō, a loaʻa kahi patent. no CYB004 e hoʻoikaika hou i kāna kōpili IP.
Ua ʻōlelo ʻo CEO Doug Drysdale, ua hoʻomau ka ʻoihana i ka holomua nui i ka wā o ka hapaha i ka hoʻonui ʻana i kā lākou molekele i hoʻokumu ʻia i ka psychedelic proprietary i ka hoʻomohala ʻana i ka lāʻau lapaʻau, e hōʻea ana i nā milestones regulatory, e hoʻopau ana i nā haʻawina preclinical a me ka hoʻokumu ʻana i nā kaulahao lako pono i ka US a me UK.
